Asphelia to Present At 2008 BIO International Convention in San Diego
Posted on: Tuesday, 10 June 2008, 09:00 CDT
SAN DIEGO, June 10, 2008 (PRIME NEWSWIRE) -- Asphelia Pharmaceuticals, a privately-held, clinical-stage company focused on the development of novel therapeutics for the treatment of immunological disorders, will be presenting at the 2008 BIO International Convention on June 19th at 3PM PT in Room 5A of the San Diego Convention Center. The Biotechnology Industry Organization (BIO) is a trade association that hosts the BIO International Convention, to be held this year in San Diego, CA from June 17th to June 20th. BIO is the world's largest biotechnology organization, providing advocacy, business development, and communications services to more than 1,150 members worldwide.
Francois-Xavier Frapaise MD, President and CEO of Asphelia, will provide an overview of Asphelia's core-assets, including a trichuris suis ova-based therapy (ASP 1002) and an oral integrin and adhesion molecule antagonist (ASP 2002). Dr. Frapaise's presentation will be focused on the immunomodulating effects of Helminths and the use of this novel therapeutic approach in the treatment of immunological disorders such as Crohn's Disease, Multiple Sclerosis, as well as allergic conditions. The Helminths technology is currently being assessed in a number of clinical studies being conducted globally. Dr. Frapaise will also be available for individual meetings before and after his presentation.
About Asphelia Pharmaceuticals, Inc.
Asphelia Pharmaceuticals is a privately-held, clinical-stage company poised to change the course of immunological disorders. Asphelia is focused on the development of therapies for Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), as well as other immunological and inflammatory disorders, including Multiple Sclerosis and Asthma. Asphelia's core assets target the causes of Inflammatory Bowel Disease, not just its symptoms, providing viable alternatives to the current standards of care.
This news release was distributed by PrimeNewswire, www.primenewswire.com
CONTACT: Asphelia Pharmaceuticals, Inc. Xavier Frapaise (858) 731-8520 xfrapaise@aspheliapharma.com
Source: PrimeNewswire
Related Articles
- Asphelia Pharmaceuticals Announces Fall 2008 Conference Schedule
- Asphelia Pharmaceuticals Forms Premier Scientific Advisory Board
- Oncolytics Biotech Inc. To Present at BIO 2008 International Convention
- Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
- Asphelia Pharmaceuticals Appoints Francois-Xavier Frapaise As President and Chief Executive Officer
- Callisto Announces Presentation at the BIO Annual International Convention and Auditor's Going Concern Opinion
- EPIX Pharmaceuticals to Present at the BIO 2007 International Convention
- Argos Therapeutics Announces Participation in BIO 2007 International Convention Business Forum
- GNI Researchers Identify Important Regulator and Associated Signaling Cascade in Human Immunological Disorders; Research Findings to Be Published in Prestigious PNAS Journal
- BioSante Pharmaceuticals, Inc. To Present at BIO Annual International Convention on April 11 in Chicago
 |
 |
User Comments (0)
RSS Feeds